Wegovy, weight loss
Independence Blue Cross to stop covering Wegovy, Ozempic as weight loss drugs in 2025
Independence Blue Cross said starting Jan. 1 it will only be covering GLP-1 agonists — commonly sold under brand names like Wegovy and Ozempic — when prescribed for their Food and Drug Administration -approved uses. That includes type 2 diabetes and cardiovascular disease.
GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...
Neither drug is considered as effective as the brand-name weekly injections sold for diabetes and weight loss as Ozempic and Wegovy by Novo Nordisk and Mounjaro and Zepbound by Eli Lilly. Still, ...
Recently published studies assert that Ozempic significantly increases the risk of developing a rare eye condition called non ...
The world’s largest food and beverage company said it plans to launch a frozen food brand that will cater to consumers who ...
But in an increasingly competitive market for weight loss drugs, these are not the only options for people looking to lose ...
PERSPECTIVES: The resurgence of Y2K skin-baring fashion trends coincides with the rise of prescription weight loss drugs like ...
As new research suggests those taking GLP-1 drugs have fewer hospitalisations for alcoholism, a leading specialist warns ...
Maryland’s Medicaid program now offers partial coverage of popular obesity drugs, with the state spending more than $68 ...
Semaglutide, the active ingredient in Ozempic and Wegovy, has been linked to a condition that can cause permanent vision loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback